Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2010-09-22
Target enrollment:
Participant gender:
Summary
Study Objectives
1. To evaluate the efficacy of the combination of dexamethasone (Decadron®), thalidomide
(Thalomid®), and lenalidomide (Revlimid®) as therapy for patients with relapsed or
refractory multiple myeloma (MM) who have failed prior treatment with both lenalidomide
and thalidomide when used as monotherapies.
2. To evaluate the safety of the combination of lenalidomide, dexamethasone, and
thalidomide as a therapy for patients with relapsed or refractory multiple myeloma.